- CH₣46.96bn
- CH₣50.68bn
- CH₣6.53bn
Lonza to sell capsule and health ingredients business to Lone Star for $3.0 billion
Table: Swiss trade surplus at CHF 3.818 bln in January
Europe Research Roundup: Ageas, Evotec, Sandvik
Swiss stocks - Factors to watch on February 3
Table: Swiss trade surplus at CHF 1.036 bln in December
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Switzerland's Lonza edges closer to sale of its capsule and health ingredients business
Contract drug manufacturer Lonza forecasts slower sales growth for 2026 (updated)
Lonza forecasts 2026 sales growth of 11-12% for core CDMO business
Swiss stocks - Factors to watch on January 28
Brief: Lonza FY Sales Growth 21.7%
Lonza forecasts 2026 sales growth of 11-12% for core CDMO business
Lonza Group AG misses 2025 sales estimates, sees FX headwinds in 2026
Table: Swiss trade surplus at CHF 3.841 bln in November
BNP picks medtech favourites, sees re-rating in H2 2026
Europe Research Roundup: Amundi, Continental, S4 Capital
Table: Swiss trade surplus at CHF 4.32 bln in October